Ovarian endometrioid adenocarcinoma
MONDO:0006335An endometrioid adenocarcinoma arising from the ovary. It comprises 10% to 25% of all primary ovarian carcinomas. Grossly, endometrioid carcinoma may present as a cystic or solid mass. Microscopically, the tumor greatly resembles the appearance of the ordinary type of endometrial adenocarcinoma. As a group, endometrioid carcinoma has a prognosis twice as good as that of serous or mucinous carcinoma.
Also known as: endometrioid adenocarcinoma of ovary, endometrioid adenocarcinoma of the ovary, endometrioid cancer of ovary, endometrioid cancer of the ovary, endometrioid carcinoma of ovary, endometrioid carcinoma of the ovary, endometrioid ovary carcinoma, endometrium adenocarcinoma of ovary
2936 clinical trials for this condition and its sub-types, 78 tagged with Ovarian endometrioid adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Ovarian endometrioid adenocarcinoma
-
Can a targeted drug keep ovarian cancer at bay longer?
Disease control Not yet recruitingThis trial is testing whether a targeted therapy called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with newly diagnosed advanced ovarian cancer live longer without their cancer growing. Participants have already completed first-line platinum-…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
Disease control Not yet recruitingThis trial is testing whether a new drug called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer and delay cancer growth compared to standard chemotherapy. The study includes adults with high-grade serous or…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a targeted drug duo hold off ovarian cancer's return?
Disease control Not yet recruitingThis trial tests whether raludotatug deruxtecan, given alone or with bevacizumab, can delay cancer growth better than standard care in people with platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer that has returned after first treatment. About 600 adults as…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for ovarian cancer: targeted drug combo takes on resistant tumors
Disease control Not yet recruitingThis phase II trial compares a new two-drug combination (sacituzumab govitecan plus bevacizumab) against standard chemotherapy (carboplatin, liposomal doxorubicin, and bevacizumab) in 87 women with platinum-sensitive ovarian cancer that has progressed after PARP inhibitor mainten…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug combo aims to improve ovarian cancer maintenance with fewer dropouts
Disease control Not yet recruitingThis trial tests whether fluzoparib plus bevacizumab works as well as the standard olaparib plus bevacizumab for maintenance therapy in women with HRD-positive advanced ovarian cancer after initial chemotherapy. The study enrolls about 120 participants and tracks how long they st…
Phase 2 • Sponsor: Shandong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo aims to extend remission in advanced ovarian cancer
Disease control Not yet recruitingThis study tests whether a combination of two drugs (fluzoparib and famitinib) can help keep advanced ovarian cancer from returning after successful initial chemotherapy. About 43 women with stage III-IV ovarian cancer who responded to platinum-based chemo will take these pills d…
Phase 2 • Sponsor: Jinhua Zhou • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Mapping the DNA test that decides who gets PARP inhibitors
Diagnosis Not yet recruitingResearchers are reviewing medical records from about 1,125 women in Italy with newly diagnosed advanced high-grade epithelial ovarian cancer. The study focuses on how hospitals test tumors for homologous recombination deficiency (HRD), a DNA repair flaw that can make PARP inhibit…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC